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Abstract—Cancerous diseases are being responsible for the
death of many around the globe. Treating these illnesses pose
a significant challenge to the medical professionals. While con-
ventional methods, chemotherapy or radiotherapy for example,
provide a remedy to the issue their side effects are not negligible.
In the past few decades new methods have emerged, which could
hinder the strength of the side effects and most remarkably, anti-
angiogenic therapy can make a notable difference in every day
cancer treatment. While the technique has many advantages the
cost of treatments are often expensive due to the non-personalized
administration medical protocols. In this paper a model based
solution is provided which aims to lower the medical expenses
during the treatment by creating personalized administration
plans with the help of control engineering.
Index Terms—Model Predictive Control, Robust Fixed Point
Transformation, tumor, MPC, RFPT.
I. INTRODUCTION
Cancer related illnesses are one of the leading cause of death
in the European Union with 1.359.500 causalities in 2016
according to Malvezzi et al. [1]. Conventional cancer therapy
methods such as surgical intervention, chemotherapy, and
radiotherapy are used widely in order to treat these diseases.
While they are proven to be effective in the majority of cases,
many side effect arose during the treatment process. In the
past decades a new methodology appeared called Targeted
Molecular Therapies (TMT) which targets the key mechanisms
of tumor growth [2]. This paper focuses of anti-angiogenic
therapy which is one of the targeted methods, and it aims
to eradicate the vascular network of the tumor. While this
method does not annihilate the tumor cells completely it
can reduce its size to a safe level without severely affecting
the health of the patient. After the tumor has reached its
steady-state, conventional therapies can be applied in order to
remove the remaining cancerous cells in a way that it causes
significantly less side effect compared to a simple traditional
treatment. While at first glance the method seems flawless,
one should be noted that anti-angiogenic treatment entails
significant medical expenses which can not be covered fiscally
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by the vast majority of people. However these expenses can
be decreased by creating personalized treatment plans which
aim to reduce the volume of the tumor in the shortest possible
time while considering the cost component of the medication.
Hence this paper aims to use model based control techniques in
order to create the treatment plans with the use of the famous
Hahnfeldt model in conjunction with Model Predictive Control
and Robust Fixed Point Transformation based control methods.
II. THE MODEL OF THE SYSTEM
In order to create a personalized treatment plan it is nec-
essary to have a mathematical model which describes the
change in the volume of the tumor under anti-angiogenic
intervention. In this paper the Hahnfeldt model is used which
is introduced by Hahnfeldt et al. [3] in 1999 and it describes
the tumor growth process considering the significant aspects
of the anti-angiogenic therapy. While the model is accurate
in the vast majority of the cases, one should be alarmed
that since its creation scientist has identified many other
alternate vascularization methods which govern the tumor
growth, Intussusceptive Microvascular Growth or Vessel Co-
Option for example [4]. The equations that describe the system
are the following [3]:
𝑉 ′ = −𝜆1𝑉 ln
(
𝑉
𝐾
)
𝐾 ′ = −𝜆2𝐾 + 𝑏𝑉 − 𝑑𝐾𝑉 2/3 − 𝑒𝐾𝑔(𝑡)
𝑔(𝑡) =
∫ 𝑡
0
𝑐(𝜏) exp(−𝑐𝑙𝑟(𝑡− 𝜏))d𝜏
(1)
The first equation describes the change in the volume
of the tumor by the Gomperzian tumor growth model. 𝑉
denotes the volume of the tumor (𝑚𝑚3), 𝐾 is the volume
of the vasculature (endothelial) (𝑚𝑚3) and 𝜆1 is the growth
parameter of the tumor (1/𝑑𝑎𝑦). The second equation governs
the change of the vasculature where 𝜆2 is responsible for
the sudden decreasement in the functional vasculature of
the tumor (1/𝑑𝑎𝑦), 𝑏 is the angiogenic factor (1/𝑑𝑎𝑦), 𝑑
describes the cellular blocking mechanisms of the vasculature
(1/𝑛𝑎𝑝 ⋅𝑚𝑚2), 𝑒 is the inhibition of the vasculature with the
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medication (𝑘𝑔/𝑑𝑎𝑦 ⋅𝑚𝑔), and finally 𝑔(𝑡) is the concentration
of the administered inhibitor (𝑚𝑔/𝑘𝑔). The last equation
describes the concentration of the inhibitor in the patient by
incorporating the concentration of the previously administered
medications (𝜏 < 𝑡). Function 𝑐(𝜏) is the rate of administration
of inhibitor concentration at 𝜏 and 𝑐𝑙𝑟 is the clearance of the
medication (1/𝑑𝑎𝑦).
The model slightly varies if one considers the systems
engineering approach. The first part in the second equation on
the right hand side disappears, since it has negligible effects
on the overall dynamics and also 𝑔(𝑡) will be the input of the
system. According to Sa´pi et al. the modified model which
will be used in this paper is [5]:
𝑥1 = −𝜆1𝑥1ln
(
𝑥1
𝑥2
)
𝑥2 = 𝑏𝑥1 − 𝑑𝑥2/31 𝑥2 − 𝑒𝑥2𝑔(𝑡)
𝑦 = 𝑥1
(2)
where 𝑥1 = 𝑉 , 𝑥2 = 𝐾 and the output of the system is the
volume of the tumor. Simulations showed that the final tumor
and vasculature volume without treatment is approximately
1.734 ⋅104 𝑚𝑚3 which will be used as an initial condition. In
order to create linear controllers in the following chapters, the
model has to be linearized. The linearization was done around
the 𝑔(𝑡) = 0 working point and the state-space matrices for
arbitrary 𝑥1 and 𝑥2 are:
𝐴 =
⎡
⎢⎢⎢⎣
−𝜆1ln
(
𝑥1
𝑥2
)
− 𝜆1 𝜆1𝑥1
𝑥2
𝑏− 2
3
𝑑𝑥
−1/3
1 𝑥2 −𝑑𝑥2/31
⎤
⎥⎥⎥⎦
𝐵 =
[
0
−𝑒𝑥2
]
𝐶 =
[
1 0
]
𝐷 =
[
0
]
(3)
III. MODEL PREDICTIVE CONTROL DESIGN
In order to tackle the main issue of the paper it is straightfor-
ward to use a cost function which takes monetary expenses and
treatment time into consideration. Model Predictive Control
(MPC) is capable of ensuring this condition in conjunction
with additional constraints. As stated in Camacho et al.,
MPC consists of three main ingredients namely prediction,
optimization, and execution [6]. The algorithm predicts how
the states evolve in every time step based on the discrete model
of the system. After that, an optimization algorithm computes
an optimal control sequence which minimizes a cost function
that incorporates the above mentioned criterias. In the last step
the first member of this sequence is applied to the real system
and the procedure repeats.
In this paper, both nonlinear MPC and its linear counterpart
is used to create tumor regulating controllers. To this extent
the continuous models - both nonlinear and linear - has to
be discretized so that it takes the form 𝑥+ = 𝑓(𝑥, 𝑢). A
simple linear approximation was applied to the model to
keep the algorithm computationally reasonable in exchange
of precision. The discrete nonlinear model then holds the
following form, where Δ𝑡 is the sampling time which has
to be fairly small in order to gain accurate approximations:
𝑥+1 = 𝑥1 +Δ𝑡[−𝜆1𝑥1ln(𝑥1/𝑥2)]
𝑥+2 = 𝑥2 +Δ𝑡[𝑏𝑥1 − 𝑑𝑥2/31 𝑥2 − 𝑒𝑥2𝑔]
(4)
In this representation, variables 𝑥1, 𝑥2 and 𝑔 now depends
on 𝑛 ∈ ℕ instead of 𝑡 ∈ ℝ, and 𝑥+ denotes the next value of
the variable (the 𝑛+ 1 step).
The discrete time matrices can be obtained by the following
simple equations according to Chen et al. [7]:
𝐴𝑑 = 𝐼 +Δ𝑡𝐴
𝐵𝑑 = Δ𝑡𝐵
𝐶𝑑 = 𝐶
𝐷𝑑 = 𝐷
(5)
With equation (4) a nonlinear controller can be created. To
this extent a suitable cost has to be chosen which will be
denoted by ℓ(𝑛, 𝑥, 𝑢). According to Gru¨ne et al. the cost has
to be selected so that ℓ(𝑛, 𝑥∗, 𝑢∗) = 0 and ℓ(𝑛, 𝑥, 𝑢) > 0,∀𝑥 ∈
𝑋, ∀𝑢 ∈ 𝑈 where 𝑥∗ and 𝑢∗ are the desired states and input
signals, 𝑋 = ℝ2 is the state space and 𝑈 = ℝ is the control
space [8]. Based on this, ℓ(𝑛, 𝑥, 𝑢) takes the following form:
ℓ(𝑛, 𝑥, 𝑢) = 𝜁 ∥𝑥− 𝑥𝑟𝑒𝑓 (𝑛)∥2 + 𝜉 ∥𝑢− 𝑢𝑟𝑒𝑓 (𝑛)∥2 (6)
where 𝜁, 𝜉 ∈ ℝ are control parameters. As one can see,
this cost is designed to incorporate time-varying references as
well as constant signals thus the controller can handle custom
prescriptions which makes the algorithm more flexible in cases
where medical professionals has to specify tumor reduction
along some trajectory. Because the model is a single-input
single-output (SISO) system and the goal is to control the
volume, the cost can be further simplified to:
ℓ(𝑘, 𝑥1, 𝑢) = 𝜁(𝑥1 − 𝑥𝑟𝑒𝑓 (𝑘))2 + 𝜉𝑢2 (7)
With this time-varying prescription a proper cost function
can be introduced which a nonlinear optimization algorithm
minimizes. The cost function is given by the following equa-
tion [8]:
min
𝑢(⋅)∈𝕌𝑁 (𝑥0)
𝐽𝑁 (𝑛, 𝑥0, 𝑢(⋅)) :=
𝑁−1∑
𝑘=0
ℓ(𝑛+ 𝑘, 𝑥𝑢(𝑘, 𝑥0), 𝑢(𝑘))
(8)
In equation (8) 𝑥0 is the current measurement of the states,
𝑁 > 2 ∈ ℕ+ is the prediction horizon, 𝑥𝑢(𝑘, 𝑥0) represents
the prediction of the system based on the discrete model
(4) and it can be computed iteratively by 𝑥𝑢(0, 𝑥0) = 𝑥0,
𝑥𝑢(𝑘 + 1, 𝑥0) = 𝑓(𝑥𝑢(𝑘, 𝑥0), 𝑢(𝑘)), 𝑢(⋅) ∈ 𝕌𝑁 (𝑥0) denotes
control sequence of length 𝑁 which are the free variables
in the optimization, and 𝕌𝑁 (𝑥0) is the constrained control
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sequence space for each measurement. It is important to
impose constraints on the optimization process beacuse in
certain cases the applied dosage may exceed a critical level
thus the health of the patient can be jeopardized. The final
step in the algorithm is to apply the first control signal of the
calculated sequence.
In the case of linear MPC, equation (5) has to be trans-
formed into an augmented state-space model which leads to a
simplified cost function according to Wang et al. [9]:
⎡
⎣Δ𝑥𝑛+1
𝑦𝑛+1
⎤
⎦ =
⎡
⎣ 𝐴𝑑 𝑜𝑇
𝐶𝑑𝐴𝑑 1
⎤
⎦
⎡
⎣Δ𝑥𝑛
𝑦𝑛
⎤
⎦+
⎡
⎣ 𝐵𝑑
𝐶𝑑𝐵𝑑
⎤
⎦Δ𝑢𝑛
𝑦𝑛 =
[
𝑜 1
]
⎡
⎣Δ𝑥𝑛
𝑦𝑛
⎤
⎦
(9)
In these equations, Δ𝑥𝑛+1 = 𝑥𝑛+1−𝑥𝑛, Δ𝑢𝑛 = 𝑢𝑛−𝑢𝑛−1
are incremental variables, and 𝑜 = [0 0]. Two more vectors
has to be introduced in which one contains the predictions,
and one carries the free variables of optimization in terms of
Δ𝑢, hence
𝑌 =
⎡
⎢⎢⎢⎣
𝑦𝑘+1
𝑦𝑘+2
.
.
.
𝑦𝑘+𝑁𝑝
⎤
⎥⎥⎥⎦ ,Δ𝑈 =
⎡
⎢⎢⎢⎣
Δ𝑢𝑘
Δ𝑢𝑘+1
.
.
.
Δ𝑢𝑘+𝑁𝑐−1
⎤
⎥⎥⎥⎦ (10)
With these vectors and matrices in hand, the predictions can
be computed by the following equation:
𝑌 = 𝐹𝑥(𝑘) + ΦΔ𝑈 (11)
where 𝑥(𝑘) is the current measured state of the system,
𝐹 =
⎡
⎢⎢⎢⎣
𝐶𝐴
𝐶𝐴2
.
.
.
𝐶𝐴𝑁𝑝
⎤
⎥⎥⎥⎦ (12)
Φ =
⎡
⎢⎢⎢⎢⎢⎣
𝐶𝐵 0 ⋅ ⋅ ⋅ 0
𝐶𝐴𝐵 𝐶𝐵 ⋅ ⋅ ⋅ 0
𝐶𝐴2𝐵 𝐶𝐴𝐵 ⋅ ⋅ ⋅ 0
.
.
.
𝐶𝐴𝑁𝑝−1𝐵 𝐶𝐴𝑁𝑝−2𝐵 ⋅ ⋅ ⋅ 𝐶𝐴𝑁𝑝−𝑁𝑐𝐵
⎤
⎥⎥⎥⎥⎥⎦
(13)
𝑁𝑝 is the prediction horizon, and 𝑁𝑐 is the control horizon
with 𝑁𝑝 < 𝑁𝑐. One should be aware that in vector (12) and
matrix (13) the matrices 𝐴,𝐵 and 𝐶 are coming from the
augmented state-space model. Upon possessing equation (11),
the cost function can be formulated as
𝐽𝑁𝑐(𝑥(𝑘),Δ𝑈) = (𝑅𝑠− 𝑌 )𝑇 (𝑅𝑠− 𝑌 ) +Δ𝑈𝑇𝑅𝑤Δ𝑈 (14)
where 𝑅𝑤 is a weighting 𝑁𝑐 by 𝑁𝑐 identity matrix with
some constant multiplier 𝜉 ∈ ℝ, 𝑅𝑠 denotes the reference
trajectory with 𝑅𝑠 = [𝑟𝑘+1 𝑟𝑘+2 ⋅ ⋅ ⋅ 𝑟𝑘+𝑁𝑝 ]𝑇 and 𝑟𝑘+𝑖 (𝑖 ∈
ℕ
+, 0 < 𝑖 ≤ 𝑁𝑝) contains the information about the reference
trajectory at time instant 𝑘. Analytic solution exists for Δ𝑈
if there are no constraints and it is given by the following
equation:
Δ𝑈 = (Φ𝑇Φ+𝑅𝑤)
−1Φ𝑇 (𝑅𝑠 − 𝐹𝑥(𝑘)) (15)
While this result is computationally inexpensive, this is
just an Linear Quadratic Regulator with finite horizon which
implies that better results can be obtained with the infinite
horizon case as pointed out by Mayne et al. [10]. Hence this
controller is only used for the sake of comparison and the
control vector Δ𝑈 is computed by an optimization algorithm
that can deal with additional constraints.
IV. ROBUST FIXED POINT TRANSFORMATION
The Robust Fixed Point Transformation (RFPT) based adap-
tive control is a novel control engineering method introduced
by Tar et al. in [11]. While it is a nonlinear method, it has the
profound advantage that it is easy to design controllers with
it contrary to Lyapunov’s 2nd method. The only downside
is that the controller does not provide an optimal solution
in the traditional sense and it is only capable of tracking
time-varying reference signals efficiently. However nonlinear
methods are more precise by nature, also the paper deals with
time-varying reference signals which justifies the use of RFPT.
The underlying concept is the realized-response scheme. If one
inverts the system model in a fashion that from the reference
trajectory a proper control signal can be obtained which then
applied to the plant will control the physical system to the
desired regime. While in theory the method works, one should
be aware that mathematical models are seldom accurate or
complete. This results in a realized response which completely
differs from the desired case. The role of the RFPT method
is to slightly perturb the desired trajectory in every control
cycle iteratively so that the realized response meets with the
desired. Detailed description about the method can be found in
[11],[12],[13]. The first part of the control cycle is a kinematic
prescription which is given by
𝑒𝑖𝑛𝑡(𝑡) =
∫ 𝑡
𝑡0
(𝑞𝑛(𝜏)− 𝑞(𝜏)) d𝜏 ,
(
d
d𝑡
+ Λ)𝑛+1𝑒𝑖𝑛𝑡 = 0
(16)
where 𝑞𝑛 is the reference trajectory, 𝑞 is the measured state,
𝑛 is the order of the system and Λ is a control parameter. In
the case of the Hahnfeldt model this leads to the following
prescription:
𝑒𝑖𝑛𝑡(𝑡) =
∫ 𝑡
𝑡0
(𝑥𝑛1 (𝜏)− 𝑥1(𝜏)) d𝜏 ,
?˙?𝑑1 = Λ
2𝑒𝑖𝑛𝑡 + 2Λ𝑒+ ?˙?
𝑛
1
(17)
In equation (17) 𝑥𝑛1 is the reference volume of the tumor,
and ?˙?𝑑1 is the output of the kinematic block. This value is given
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to the deform function, which in this simple SISO case is the
following fixed point problem:
𝐺(𝑟∣𝑟𝑑) 𝑑𝑒𝑓= (𝑟 +𝐾)[1 +𝐵 tanh(𝐴[𝑓(𝑟)− 𝑟𝑑])]−𝐾
𝐺(𝑟𝑑∗ ∣𝑟𝑑) = 𝑟𝑑∗ if 𝑓(𝑟𝑑∗) = 𝑟𝑑
𝐺(−𝐾∣𝑟𝑑) = −𝐾 if 𝑟 = −𝐾
(18)
Constants 𝐴,𝐵,𝐾 are free control parameters, 𝑓(𝑟) is the
measured signal, 𝑟𝑑 is the output of the kinematic block,
namely ?˙?𝑑1 and 𝑟𝑑∗ is the solution of the fixed point problem
for which the realized response of the system coincides with
the desired trajectory. Variable 𝑟 is responsible for the fixed
point iteration so that 𝑟𝑛+1 = 𝐺
(
𝑟𝑛∣𝑟𝑑
)
. In order to establish
a proper control signal, the inverse of the model has to be
constructed. If one takes equation (2) and rearrange the terms,
it leads to
𝑥2 = 𝑥1exp
(
− 𝑥1
𝜆𝑥1
)−1
(19)
Differentiating this expression results in
𝑥2 =
𝑥1𝑓 + 𝑥1𝑓
𝑥1𝑥1𝜆− 𝜆?˙?21
(𝜆𝑥1)2
𝑓2
(20)
where 𝑓 denotes the exponential term in (19). This can be
further simplified to
𝑥2 =
𝜆?˙?1𝑥1 + 𝑥1𝑥1 − ?˙?21
𝑓𝜆𝑥1
(21)
Substituting this into the second equation in (2) in conjunc-
tion with equation (19) yields
𝑔(𝑡) = −𝜆?˙?1𝑥1 + 𝑥1𝑥1 − ?˙?
2
1 + 𝜆𝑑𝑥
8/3
1 − 𝜆𝑏𝑥1𝑓
𝜆𝑒𝑥21
(22)
which is the inverse model of the system. Applying the output
of the deform function to this inverse leads to a proper
control signal 𝑔(𝑡) which drives the system along the desired
trajectory.
V. SIMULATION RESULTS
Multiple simulations were conducted with the tracking con-
trollers in MATLAB/Simulink. The nonlinear MPC prototype
is based on the work of Gru¨ne et al., and the optimization
uses the fmincon MATLAB routine, while in the linear case
routine quadprog were used [8]. The simulation parameters
were chosen according to Sa´pi et al. thus 𝜆1 = 0, 192, 𝑏 =
5, 85, 𝑑 = 0, 00873 and 𝑒 = 0, 66 [5]. The initial value of the
tumor was 𝑥0 = 1.734 ⋅ 104 in every case because it can be
interpreted as a worst-case scenario so one can assume that for
smaller values the results are better. For time-varying reference
the following prescription was used:
𝑥𝑛(𝑡) = −tanh(𝑐𝑡)(𝑥0 − 1) + 𝑥0 (23)
Figure 1. depicts the curves for different values of 𝑐. For the
simulations the value were 𝑐 = 0.1 since it provides a middle
ground between the duration of treatment and the steepness of
the curve (which can lead to higher dosages). The argument
for the −1 term is that the system can not be controlled to
zero tumor volume, which could lead to issues in the case
of RFPT controllers. The length of the simulations were 100
days with fixed 0.1 step size and they were conducted using
the ODE3 solver of Simulink.
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Fig. 1. Reference trajectories for different values of 𝑐
Multiple values of saturation were imposed on the input
signal, namely 25, 15, 13 𝑚𝑔/𝑘𝑔, which were responsible for
keeping the administration at a safe level for the patients. The
treatment was successful if the tumor reached 10𝑚𝑚3 volume
or less. The scrutinized attributes of the simulations were the
following: the volume of the tumor in steady state (𝑚𝑚3),
total inhibitor concentration during the treatment (𝑚𝑔/𝑘𝑔),
duration of tumor reduction to 10 𝑚𝑚3 (𝑑𝑎𝑦𝑠), total inhibitor
concentration to 10 𝑚𝑚3 volume and steady state inhibitor
concentration 𝑚𝑔/𝑘𝑔.
In the case of linear MPC, simulations showed that there
is a combination of parameters that provides an optimal
solution that can not be improved furthermore regard to
the total concentration and duration of the treatment, thus
𝑁𝑝 = 𝑁𝑐 = 10, 𝑥1 = 𝑥2 = 10 (which are the working
points of linearization), and 𝜉 = 1.3 ⋅ 104 (which corresponds
to matrix 𝑅𝑤). The best results were achieved for constant
0 reference volume with 25 𝑚𝑔/𝑘𝑔 saturation for which
the reduction time was 44.64 𝑑𝑎𝑦𝑠 and the concentration
during reduction was 870.7𝑚𝑔/𝑘𝑔. However the time-varying
reference tracking capabilities of the controller were weak
which can be attributed to the linear nature of the controller.
For the simulation of the nonlinear MPC, the prediction
and control horizon was 𝑁𝑐 = 𝑁𝑝 = 10 because it provided
trustworthy results while it was not very expensive compu-
tationally. The simulations examined the behaviour of the
controller for different levels of saturations, and values of 𝜁
which were chosen from the interval 𝜁 ∈ [750; 1250] because
for other values the system became unstable as a result of
the singularities in the system model. However the weighting
factor on the control was 𝜉 = 1 in every case because it also
resulted in pathological behaviour of the system. For constant
𝑥1 = 0 reference, the best results came from 𝜁 = 1000 for
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25 𝑚𝑔/𝑘𝑔 saturation. Results for different values of 𝜁 can be
seen in Table I. For time-varying reference, the tracking error
remained significant however it was better than the linear case.
The tumor reduction can be seen on Figure 2. in conjunction
with the treatment protocol on Figure 3.
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Fig. 2. Tumor reduction with the nonlinear MPC controller
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Fig. 3. Administration protocol with the nonlinear MPC controller
The last simulations were performed on the RFPT controller.
Since it is only able to track time-varying references, the
constant cases were omitted. The controller parameters were
𝐵 = -1,𝐾 = 5, 3 ⋅ 1010, 𝐴 = 10-11 and Λ = 1. For the
examined reference volume, only saturation 25 𝑚𝑔/𝑘𝑔 was
applicable because in other cases, the controller failed to keep
the system in the convergence region due to the insufficient
maximum amount of admissible inhibitor which is required
by controller to maintain a precise tracking. Despite these
facts, the RFPT controller vastly outperformed the other MPC
variants for tracking time-varying references which means that
this method is the best for a flexible treatment. The reduction
can be seen on Figure 4. with the tracking error on Figure 5.
The produced protocol can be viewed on Figure 6.
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Fig. 4. Tumor reduction with the RFPT controller
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Fig. 5. Tracking error with the RFPT controller
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Fig. 6. Administration protocol with the RFPT controller
VI. CONCLUSION
In this paper, several controllers were designed and tested
in order to regulate the volume of a tumor by the help of
anti-angiogenic therapy. One can draw the conclusion that
linear techniques are not sufficient for solving such an unstable
nonlinear problem thus their use in a systems biology envi-
ronment is highly questionable. However, nonlinear controllers
provided excellent results for tracking both constant and time
varying reference signals. For the constant case, nonlinear
MPC proved to be efficient for different saturation levels,
and for time-varying signals RFPT provided accurate results.
However it should be noted that the model and the controllers
have to be improved. Further work has to be devoted into
incorporating new scientific results into the model. For the
controllers, one must examine their behaviour under parameter
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𝜻 (𝑚𝑔/𝑘𝑔)
Saturation
(𝑚𝑚3)
volume
tumor
state
Steady
(𝑑𝑎𝑦𝑠)
reduction
of
Duration
(𝑚𝑔/𝑘𝑔)
reduction
during
concentration
Total
750
13 3, 09 83, 8 1089
15 0, 89 64, 69 970, 1
25 0, 81 36, 1 891, 6
850
13 3, 09 83, 8 1089
15 0, 83 59, 48 892, 1
25 0, 76 36, 1 890, 5
1000
13 3, 09 83, 8 1089
15 0, 77 59, 48 892, 1
25 0, 7 30, 6 764
1150
13 3, 09 83, 8 1089
15 0, 72 64, 68 970, 1
25 0, 65 36, 1 894, 4
1250
13 3, 093 78, 6 1022
15 0, 69 59, 48 892, 1
25 0, 628 33, 3 765, 8
TABLE I
NONLINEAR MPC PERFORMANCE FOR DIFFERENT VALUES OF 𝜁
uncertainties and also their stability, but other modern control
engineering techniques can be investigated (LPV control [14],
fractional-order control [15]). In this paper the preliminary
results justify the further researches which can provide a
remedy in a safe way for the expenses in anti-angiogenic
cancer treatment.
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